Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen

Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells

(2015) Florian Rothweiler et al.   NEOPLASIA

Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer

(2013) Peter Nygren et al.   ACTA ONCOLOGICA

Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines

(2013) Věra Králová et al.   ANTI-CANCER DRUGS

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer

(2013) Peter Nygren et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Chemotherapy-Associated Angiogenesis in Neuroblastoma Tumors

(2012) Martin Michaelis et al.   AMERICAN JOURNAL OF PATHOLOGY

Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution

(2012) Laura Ceballos et al.   BMC Veterinary Research

Predicting New Indications for Approved Drugs Using a Proteochemometric Method

(2012) Sivanesan Dakshanamurthy et al.   JOURNAL OF MEDICINAL CHEMISTRY

The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses

(2011) F Durupt et al.   CANCER GENE THERAPY

Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma

(2011) Irina Dobrosotskaya et al.   Endocrine Practice

Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme

(2011) Ren-Yuan Bai et al.   NEURO-ONCOLOGY

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

(2011) M Michaelis et al.   Cell Death & Disease

The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma

(2010) P. A. Spagnuolo et al.   BLOOD

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

(2010) J. Carr-Wilkinson et al.   CLINICAL CANCER RESEARCH

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer

(2009) Mohammad H. Pourgholami et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3

(2009) M. Michaelis et al.   CANCER RESEARCH

Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis

(2009) K Weber et al.   GENE THERAPY

Flubendazole in cystic echinococcosis therapy: Pharmaco-parasitological evaluation in mice

(2009) Laura Ceballos et al.   PARASITOLOGY INTERNATIONAL

Structural and Functional Basis for Therapeutic Modulation of p53 Signaling

(2008) E. A. Bassett et al.   CLINICAL CANCER RESEARCH

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)

(2008) Gergely Szakács et al.   DRUG DISCOVERY TODAY

Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells

(2008) N. Doudican et al.   MOLECULAR CANCER RESEARCH

A Multicolor Panel of Novel Lentiviral “Gene Ontology” (LeGO) Vectors for Functional Gene Analysis

(2008) Kristoffer Weber et al.   MOLECULAR THERAPY